Andere Sprachen eFFECTOR Therapeutics, Inc.

Aktien

A3ELKJ

US28202V2079

EFTR

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
2,2 ^USD	+1,85 %		+16,40 %	-81,17 %

04.04.	Top Absteiger am Mittag	MT
04.04.	EFFECTOR Therapeutics, Inc. gibt Topline-Ergebnisse der Phase-2-KICKSTART-Studie mit Tomivosertib in Kombination mit Pembrolizumab bei nicht-kleinzelligem Lungenkrebs bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Health Care Down on Retreat From Risk -- Health Care Roundup	04.04.
Top Midday Decliners	04.04.
EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	04.04.
EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	04.04.
Top Premarket Decliners	26.03.
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	25.03.
EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	05.02.
EFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	25.01.
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024	09.01.
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024	09.01.
EFFECTOR Therapeutics Announces Reverse Stock Split	09.01.
EFFECTOR Therapeutics Announces Reverse Stock Split	09.01.
EFFECTOR THERAPEUTICS ANNOUNCES NEW POSITIVE INTERIM DATA FROM DOSE ESCALATION AND PHASE 2 EXPANSION COHORTS OF ZOTATIFIN IN ER+ METASTATIC BREAST CANCER PATIENTS	11.12.
EFFECTOR Therapeutics Says Study of Zotatifin in Breast Cancer Patients Yields 'Positive' Interim Data	08.12.
EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients	08.12.
EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients	08.12.
EFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients	08.12.
EFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer	28.11.
EFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer	28.11.
The role of STRIs in cancer	27.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen eFFECTOR Therapeutics, Inc.

Aktien

A3ELKJ

US28202V2079

EFTR

Andere Sprachen

Filter